Skip to content
    Clinical Trials

    FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

    FDAFDA What's New: Drugs

    FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
    The Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors demonstrate HER2 (ERBB) alterations.

    Key Takeaways

    • The FDA has granted accelerated approval to the kinase inhibitor sevabertinib (Hyrnuo) for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer harboring HER2 (ERBB) alterations.
    Read the original sourceFDA What's New: Drugs